Basic Information
| Drug ID | DDPD00495 |
|
| Drug Name | Zidovudine | |
| Molecular Weight | 267.2413 | |
| Molecular Formula | C10H13N5O4 | |
| CAS Number | 30516-87-1 | |
| SMILES | CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O | |
| External Links | ||
| DRUGBANK | DB00495 | |
| T3DB | T3D4720 | |
| PubChem Compound | 35370 | |
| PDR | 3698 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Caco-2 Permeability | -5.16 | - | -5.16 | - | ADME Research, USCD |
| Log P | 0.05 | - | 0.05 | - | HANSCH,C ET AL. (1995) |
| Melting Point | 114.0 | ℃ | 113-115 | ℃ | PhysProp |
| Water Solubility | 20100.0 | mg/L | 20100 | mg/L | PHYSICIANS DESK REFERENCE 2003) |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 65.0 | % | 65(52-75) | % | DRUGBANK | Bioavailability | 89.0 | % | 89.0 | % | PO, oral; Neonates; | DRUGBANK | Bioavailability | 65.0 | % | 65.0 | % | PO, oral; Children; | DRUGBANK | Bioavailability | 63.0 | % | 63±10 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 2600.0 | ng/ml | 2.6 | mcg/ml | PO, oral; | The Pharmacological Basis of Therapeutics | C Max | 1600.0 | ng/ml | 1.6 | mcg/ml | intravenous injection, IV; | The Pharmacological Basis of Therapeutics |
| T Max | 0.75 | h | 0.5-1 | h | PO, oral; intravenous injection, IV; | The Pharmacological Basis of Therapeutics | |
| Clearance | 0.65 | L/h/kg | 0.65±0.29 | L/h/kg | AIDS,HIV; Neonates; | DRUGBANK | Clearance | 1.1 | L/h/kg | 1.14±0.24 | L/h/kg | AIDS,HIV; Infants; | DRUGBANK | Clearance | 1.9 | L/h/kg | 1.85±0.47 | L/h/kg | AIDS,HIV; Infants; | DRUGBANK | Clearance | 1.6 | L/h/kg | 26±6 | ml/min/kg | Neonates ↓ ;Children → ;Preg, pregnant → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 1.5 | L/h/kg | 25 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.6 | L/kg | 1.6±0.6 | L/kg | Apparent volume of distribution; intravenous injection, IV; AIDS,HIV; patients; | DRUGBANK | Volume of Distribution | 1.4 | L/kg | 1.4±0.4 | L/kg | Children → ;Preg, pregnant → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.8 | L/kg | 1.8 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 1.1 | h | 1.1(0.5-2.9) | h | elimination half-life; AIDS,HIV; patients; intravenous injection, IV; | DRUGBANK | Half-life | 1.1 | h | 1.1±0.2 | h | Preg, pregnant → ;Neonates ↑ ;RD, renal impairment, Renal disease，including uremia → ;Hepatic cirrhosis, cirr ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 1.3 | h | 1.3 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 3084.0 | mg/kg | 3084.0 | mg/kg | PO, oral; mouse; | DRUGBANK | Toxicity LD50 | 3084.0 | mg/kg | 3084.0 | mg/kg | PO, oral; mouse; | T3DB |
| Eliminate Route | 29.0 | % | ~29 | % | Urinary excretion; intravenous injection, IV; Unchanged drug; | DRUGBANK | Eliminate Route | 18.0 | % | 18±5 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 34.0 | % | 30-38 | % | DRUGBANK | Protein Binding | 25.0 | % | <25 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 8.0 | mg/kg/day | 8 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for neonates | 6.0 | mg/kg/day | 6 | mg/kg/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for neonates | 4.0 | mg/kg/day | 4 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for neonates | 3.0 | mg/kg/day | 3 | mg/kg/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for neonates | 6.0 | mg/kg/day | 6 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for neonates | 4.6 | mg/kg/day | 4.6 | mg/kg/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for neonates | 4.0 | mg/kg/day | 4 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for neonates | 3.0 | mg/kg/day | 3 | mg/kg/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for neonates | 6.0 | mg/kg/day | 6 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for neonates | 4.6 | mg/kg/day | 4.6 | mg/kg/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for infants | 18.0 | mg/kg/day | 18 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for infants | 480.0 | mg/m2/day | 480 | mg/m2/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for infants | 480.0 | mg/m2/day | 480 | mg/m2/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for infants | 24.0 | mg/kg/day | 24 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for infants | 480.0 | mg/m2/day | 480 | mg/m2/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for infants | 480.0 | mg/m2/day | 480 | mg/m2/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for children | 600.0 | mg/day | 600 | mg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for children | 480.0 | mg/m2/day | 480 | mg/m2/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for children | 480.0 | mg/m2/day | 480 | mg/m2/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for children | 18.0 | mg/kg/day | 18 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for children | 480.0 | mg/m2/day | 480 | mg/m2/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for children | 480.0 | mg/m2/day | 480 | mg/m2/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for children | 24.0 | mg/kg/day | 24 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for children | 480.0 | mg/m2/day | 480 | mg/m2/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for children | 480.0 | mg/m2/day | 480 | mg/m2/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for adolescents | 600.0 | mg/day | 600 | mg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for adolescents | 480.0 | mg/m2/day | 480 | mg/m2/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for adolescents | 480.0 | mg/m2/day | 480 | mg/m2/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for adolescents | 18.0 | mg/kg/day | 18 | mg/kg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for adolescents | 480.0 | mg/m2/day | 480 | mg/m2/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for adolescents | 480.0 | mg/m2/day | 480 | mg/m2/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for adults | 600.0 | mg | 600 | mg | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for adults | 6.0 | mg/kg/day | 6 | mg/kg/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for adults | 1000.0 | mg/day | 1000 | mg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for geriatric | 600.0 | mg/day | 600 | mg/day | PO, oral | Zidovudine | zidovudine | PDR |
| Max dose for geriatric | 6.0 | mg/kg/day | 6 | mg/kg/day | intravenous injection, IV | Zidovudine | zidovudine | PDR |
| Max dose for geriatric | 1000.0 | mg/day | 1000 | mg/day | PO, oral | Zidovudine | zidovudine | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1